2.17% -0.0103

Kineta Inc (KA)

Kineta Inc (KA) 最新ニュース

Kineta Inc (KA)

Kineta Inc (KA) 最新ニュース

Quarterly Metrics: Quick and Current Ratios for Kineta Inc (KA) – DWinneX - The Dwinnex

Kineta reports progress in cancer therapy trials By Investing.com - Investing.com

Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical ... - wallstreet:online

Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical ... - wallstreet:online

Kineta: Q1 Earnings Snapshot - Houston Chronicle

BioWorld Cancer Index ends Q1 up on pipeline progress, despite restructurings - BioWorld Online

Kineta (NASDAQ:KA) Stock Price Down 7.4% - Defense World

Market Insights: Kineta Inc (KA)'s Notable Gain of 3.43, Closing at 0.49 – DWinneX - The Dwinnex

Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Markets Insider

Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In ... - Markets Insider

Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day ... - Markets Insider

Kineta Reports Progress in KVA12123 Cancer Trial - TipRanks.com - TipRanks

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

Kineta reports positive trial results for cancer therapy By Investing.com - Investing.com

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update

KA Stock Quote Price and Forecast - CNN

Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday’s Mid-D - Benzinga

S&P 500 Moves Higher; Hayward Holdings Shares Jump On Upbeat Results

Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Crude Oil Moves Higher; Best Buy Posts Upbeat Earnings

Kineta Weighs Strategic Alternatives Amid Operational Challenges - TipRanks.com - TipRanks

Healthcare Stocks on the Move Thursday: LVTX, SCTL, ENVB, RNLX, KA, IRWD, AMPE, GRFS - InvestorsObserver

Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium

Kineta to Present at Upcoming Investor Conferences

Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors

Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event

Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer

KA: Autumn Activity - Yahoo Finance

Insider Buying: Thierry Guillaudeux Acquires 10,000 Shares of Kineta Inc - Yahoo Finance

Seattle biotech firm Kineta averts Nasdaq stock delisting - Puget Sound Business Journal - The Business Journals

Kineta Stock (NASDAQ:KA), Quotes and News Summary - Benzinga

Merck Officially Commences $1.36B Imago Buyout - BioSpace

Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger ... - GlobeNewswire

Kineta, Merck Strike Deal to Pair Anti-VISTA Antibody with Keytruda - BioSpace

Yumanity selling neurology assets and merging with Kineta - Labiotech.eu

Aslan, Yumanity, Editas, Janssen and More Team Up to Fight Disease - BioSpace

Yumanity's end: J&J pays $26M for neuroscience assets as reverse merger erases biotech - Fierce Biotech

Kineta Presenting in Multiple Sessions at the Preclinical Immuno-oncology Online 2022 - PR Newswire

Kineta to Present Poster on Anti-CD27 Agonist Antibody Program at the AACR Annual Meeting 2022 - PR Newswire

Kineta Announces Patent Issuance for U.S. Patent Covering Composition of Matter of KCP506, a Novel Non-opioid ... - PR Newswire

Kineta Raises $10M in Funding - FinSMEs

KCP506 enters clinical trials for neuropathic chronic pain - Drug Discovery News

Kineta Receives Regulatory Approval for Initiation of Phase 1 Clinical Trials of KCP506 - PR Newswire

Proteostasis Therapeutics: A Clinical Stage Company That's Worth The Risk (NASDAQ:KA) - Seeking Alpha

Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies - PR Newswire

KAに似た銘柄